echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Shuzhong pharmaceutical quality disturbance: or affect the overall situation of medical reform

    Shuzhong pharmaceutical quality disturbance: or affect the overall situation of medical reform

    • Last Update: 2011-05-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: 21st century.com - 21st century economic report 2011 / 5 / 30 in order to recover the negative impact of the shutdown event on the company, Shuzhong pharmaceutical began to organize promotional activities nationwide Since May 24, some dealers in Henan Province have received the sales notice of Shuzhong Pharmaceutical Co., Ltd., listing the words "send red wine", "send hearing reader", etc However, these actions are hard to resist the trend of market collapse Longtailen company, a dealer in Nanyang, Henan Province, said: "all products of Shuzhong pharmaceutical have been removed from the shelves and returned, including western medicine varieties We no longer believe in this business " Once upon a time, Shuzhong pharmaceutical was one of the stars in the bidding for basic drugs in various regions Especially after the "Anhui model" of winning the bid at the lowest price was launched in the whole country, Shuzhong pharmaceutical has gained in almost all regions, relying on its price advantage The company's director, an Haoyi, is known as the "universal medicine maniac", whose position in the field of basic medicine "King" has not been shaken so far But all this, perhaps with a wave of returns and become the past The bigger storm is still behind On May 26, the medical reform office of the State Council held a teleconference Sun Zhigang, director of the medical reform office, said: "we need to improve the bidding and purchasing methods of traditional Chinese medicine, improve the quality evaluation and supervision system of traditional Chinese medicine, prevent vicious low price competition of enterprises, and adjust the highest guiding price of basic drug bidding in a timely manner." The drug price of the alternative Shuzhong Shuzhong pharmaceutical is not yet equal to its raw material cost, which has been widely criticized in the industry and regarded as a different kind by peers "It's not like a multibillion dollar boss to grab a seat and go to Gaza for a buffet." The reporter who interviewed anheyi left such an impression In the first time after receiving the reply of "the GMP certificate of Shuzhong pharmaceutical has been recovered" from Sichuan Provincial Drug Administration, the reporter received a phone call, saying that "anheyi is just a farmer entrepreneur", hoping to make things smaller However, Ann himself is not lack of merchant like shrewdness In the early eighties of last century, an'hao's son began to engage in medicine business in Henan, Hebei and other places It started from hoarding and curiosities After 1988, it began to set foot in Chengdu market, from medicine to chemicals, and finally to industry In 1998, it acquired the current Shuzhong pharmaceutical At the beginning of its establishment, Shuzhong Pharmaceutical Co., Ltd put its position on the grass-roots market, focusing on the general drugs familiar with the market, and directly facing the terminals below the county level Although the market is huge, it is scattered, and general large enterprises are reluctant to set foot in it, but Shuzhong pharmaceutical has persisted and achieved sales of over 100 million yuan in 2000 At the peak, there were more than 10000 people in Sichuan who were used to develop the basic market According to the data of Sichuan Provincial Food and drug administration, the sales revenue of Shuzhong in 2010 has exceeded 2.5 billion yuan In a county-level city like Guanghan in Sichuan Province, Shuzhong pharmaceutical is like a large enterprise with a relatively high salary On the recruitment bar at the company's gate, the salary given to the sales manager is "2500 + commission", which is quite competitive in the local area The industry experts who have studied the third terminal say that to enter the third terminal, it is impossible to succeed without any price advantages The price has always been a competitive tool of Shuzhong pharmaceutical, and the low price strategy does not start from the bidding of basic drugs Data shows that the price of Banlangen Granules (10g × 20) of Shuzhong pharmaceutical was 1.84 yuan before bidding in Taihe County, Anhui Province, which was lower than the bidding price of 2.35 yuan in Anhui Province in 2010 For this reason, Shuzhong pharmaceutical has been criticized in the industry and regarded as an alien by its peers Although all mainstream enterprises believe that the drug price of Shuzhong pharmaceutical is not as high as its raw material cost, due to the different market involved, large enterprises almost give up the rural market, so for many years, the well water has not violated the river water In this process, anheyi has also been building its corporate image, attributing low prices to its "green and efficient production method" At the same time, anheyi has promoted large-scale traditional Chinese medicine planting bases in Sichuan, Shaanxi and other places to enrich the company's medicinal materials sources Everything seems normal, especially on November 19, 2010, the national development and Reform Commission just organized experts to make a positive evaluation on the quality control level of Shuzhong pharmaceutical But something happened to Shuzhong pharmaceutical As many enterprises questioned, "it's not normal to sell drugs at a price lower than the cost price for a long time" After the incident, the reporter learned that anheyi was on a business trip, not in the company, and did not answer the phone No one knows what fate will be waiting for Shuzhong pharmaceutical Under the current bidding mode, essential drugs have become the chicken ribs of enterprises, while Shuzhong pharmaceutical is only the extreme case exposed under the background of the current bidding mode On May 23, Sichuan Provincial Drug Administration held a press conference to try to save some face for Shuzhong pharmaceutical At the conference, Sichuan food and Drug Administration announced five problems of Shuzhong pharmaceutical in violation of GMP regulations, such as "obsolete equipment, cracks in workshop walls, incomplete production records", and said that "no quality problems have been found in the traditional Chinese medicine products produced by the enterprise" This term is considered by the industry to be "generous" "If the GMP certification of an American enterprise is revoked, will the FDA prove that its products are good?" said Song Ruilin, executive director of China Pharmaceutical Industry Research and Development Promotion Association Many other business people think: "if the GMP regulations are not met and qualified drugs can be produced, is the GMP certificate not a piece of waste paper?" Most people in the industry believe that Shuzhong pharmaceutical uses non pharmaceutical raw materials for production, which leads to "incomplete production records" and extremely low cost Li Zhenjiang, chairman of Shenwei pharmaceutical, estimates that the cost of Compound Salvia Tablet of Shuzhong pharmaceutical is only 1/4 of that of Shenwei pharmaceutical Cai Dongchen, chairman of Shiyao group, said: "even if we use soil as raw materials, we can't make a package of Isatis for a dime." Many enterprises began to study the secret of low-cost sales of Shuzhong pharmaceutical The test results showed that the compound danshen tablet of Shuzhong pharmaceutical has obvious structure such as Danshen wood fiber It is suspected that Danshen powder may be directly used as medicine, skipping all the preparation process The low-cost bid winning policy of essential drugs is considered to be the cause of the problem of Shuzhong pharmaceutical, and the "low price only" Anhui model is a headache for many enterprises Cai Dongchen revealed: "the industry association has jointly submitted internal participation to the State Council, hoping to cancel the reference of" winning the bid at the lowest price ", even if one of the words" most "is removed Later, the Medical Reform Office approved it to the national development and Reform Commission for handling The national development and Reform Commission thought that this opinion was the voice of interest groups and would not be adopted " Before that, in November 2010, the State Council highly praised the Anhui model as "a new way for the national medical reform, providing valuable experience, which is worth learning from other provinces, regions and cities across the country", and said "to promote to the whole country" Under the guidance of this idea, Shandong, Gansu, Sichuan, Yunnan, Xinjiang and other provinces and regions clearly listed the "lowest price bid" in the bidding rules of their provinces A large number of high-quality enterprises withdrew from the bidding under the pressure of cost, and low-cost drugs became the mainstream of basic drugs According to the statistics of Zhejiang Pharmaceutical Industry Association, 74.5% of the basic drugs in China are below 10 yuan, but this phenomenon has not alleviated the problem of expensive medical treatment, and the purchase of basic drugs is rapidly shrinking Cai Dongchen said: "in 2010, China purchased 43 billion yuan of basic drugs, a year-on-year decline of 27.3% in the first quarter of this year According to this calculation, the annual purchase was about 35 billion yuan, accounting for only 8.7% of the national drug sales." It's not a big problem for enterprises to deliver this medicine free of charge " Cheap drugs can't cure the disease, which is one of the reasons why the purchasing amount of basic drugs shrinks According to our reporter, the lack of efficacy is considered to be the mystery of the low price of drugs Because the Pharmacopoeia detection technology can not avoid the deliberate addition of ingredients, the routine inspection can not detect the "melamine" in drugs A number of insiders interviewed by our reporter said that under the current bidding mode, essential drugs have become the chicken ribs of enterprises, while Shuzhong pharmaceutical is only an extreme case exposed under the background of the existing bidding mode It is related to the overall situation of medical reform China pharmaceutical promotion association and other six associations in the industry jointly proposed to amend the current Anhui model, which only takes low price, saying that Anhui model "may affect the overall situation of the success or failure of the whole medical reform" In the new round of medical reform, the basic drug system began in 2009 It is one of the important reforms If enterprises want to share the cake of the basic drug system, they must complete it through bidding This also established the important position of drug bidding in the process of medical reform However, with the emergence of the Shuzhong pharmaceutical crisis, more and more people begin to doubt the positive effect of the existing bidding method on promoting medical reform Up to now, the State Food and drug administration has not made a positive statement to the Shuzhong pharmaceutical scandal The reporter was informed that after the problem of Shuzhong pharmaceutical was found in the flight inspection of the State Food and Drug Administration on April 22, Wu Zhen, deputy director of the administration, has been supervising the matter, and plans to release the investigation situation on June 30 However, in early May after the inspection of Shuzhong pharmaceutical, the State Food and drug administration immediately organized a round of major inspection on the quality of basic drugs According to the insiders, the cause of the inspection is the quality incident of Shuzhong pharmaceutical According to the above sources, the State Food and drug administration has long been aware of the problems of Shuzhong pharmaceutical and determined that they are related to the design of the bidding system, but has been selecting appropriate investigation opportunities At the same time, the reporter also learned that various industry associations and enterprises have repeatedly expressed their opinions on the Anhui model to the drug administration and other competent departments Zhao Bowen, President of Zhejiang Medical Association, said: "all the winning Composite Danshen Tablets and Niuhuang Jiedu pills in Anhui Province have been specially calculated by experts, and the price is less than one third of the cost This will inevitably lead to quality problems " In Zhao Bowen's view, the brand enterprise's total annihilation of the basic drug market "is the great retrogression of China's health cause", because the competition among provinces in the bidding is becoming more and more popular, "the bid price of big infusion in Anhui is 0.93 yuan, that in Shandong is 0.87 yuan, and that in Zhejiang will drop." And "good medicine is eliminated" was not thought of at the beginning of Anhui model In 2010, 857 product specifications won the bid in Anhui, while only more than 550 in Sichuan It is a helpless choice for enterprises to withdraw from the competition According to Wang Bo, President of Qinmai company, more than 40% of the enterprises that actually won the bid in Anhui, Shandong and Sichuan provinces have been warned of quality at or above the provincial level in the past two years, "it is not difficult to find out the problems from the winning drugs." At the same time, due to the poor efficacy of the winning products, Anhui is still full of a large number of non-standard products Although the basic drug system requires that basic hospitals only sell basic drugs, the objective existence of demand makes many hospitals desperate "No one has applauded the Anhui model since it was launched, and the reality has shown that it will bring greater danger," Zhao said On May 24, the six major associations in the industry, such as the China Association for the promotion of drugs, jointly proposed to amend the current Anhui model, which only takes low prices, saying that the Anhui model "may affect the overall success or failure of the whole medical reform" On May 26, Sun Zhigang, deputy director of the national development and Reform Commission, said that he would "improve the bidding and purchasing methods of traditional Chinese medicine", which is a list
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.